Form 4: Inozyme Pharma Director Erik Harris Granted Stock Options

Director Erik Harris of Inozyme Pharma, Inc. was granted stock options to purchase 56,000 shares of common stock at an exercise price of $5.06 on October 3, 2024.

Summary

• Erik Harris, a director of Inozyme Pharma, Inc., was granted stock options on October 3, 2024.
• The options allow Harris to purchase 56,000 shares of Inozyme Pharma's common stock at an exercise price of $5.06 per share.
• The options vest in equal monthly installments from October 3, 2024, through October 3, 2027, and expire on October 2, 2034.
• The transaction was reported on a Form 4 filing with the Securities and Exchange Commission (SEC) on October 7, 2024.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a stock option grant. The sentiment is slightly positive as it indicates alignment of director's interests with shareholders.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes long-term commitment from the director.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The size of the grant (56,000 shares) and the vesting schedule (monthly over three years) would need to be compared to similar grants at peer companies to assess its competitiveness and appropriateness.
• Companies like BioMarin, Vertex Pharmaceuticals, and Sarepta Therapeutics could be considered peers for comparison purposes.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning the director's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates